Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network

Commentary on Twitter

Phase II CheckPAC Trial in refractory #PancreaticCancer
✅ 37.2% of pts achieved clinical benefit after stereotactic #RadiationTherapy in combination w/ nivolumab and ipilimumab
⛔ PD-L1 score was not associated with benefit

Read more: https://t.co/rxDnYvIUMl #JCO #PancSM pic.twitter.com/u7FfQEwN7a

— Journal of Clinical Oncology (@JCO_ASCO) May 9, 2022